News Shattuck Labs, Inc.

Equities

STTK

US82024L1035

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
10.59 ^USD	+8.28%		+10.54%	+48.53%

Mar. 04	Shattuck Labs, Inc. Announces Board Appointments	CI
Mar. 01	Sector Update: Health Care Stocks Rising Late Afternoon	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024	Apr. 09	GL
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference	Apr. 01	GL
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors	Mar. 04	GL
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors	Mar. 04	AQ
Shattuck Labs, Inc. Announces Board Appointments	Mar. 04	CI
Sector Update: Health Care Stocks Rising Late Afternoon	Mar. 01	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Mar. 01	MT
Shattuck Labs Shares Rise as Q4 Net Loss Narrows	Mar. 01	MT
Shattuck Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights	Feb. 29	GL
Shattuck Labs, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights	Feb. 29	AQ
Shattuck Labs Announces Participation in Upcoming March Conferences	Feb. 26	GL
Shattuck Labs Collaborates With Ono Pharmaceutical to Develop Fusion Proteins	Feb. 14	MT
Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins	Feb. 14	PR
Shattuck Strikes Joint Development Deal With Japan's Ono Pharma	Feb. 13	DJ
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases	Feb. 13	GL
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases	Feb. 13	AQ
Shattuck Labs, Inc. Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases	Feb. 13	CI
Shattuck Labs Insider Sold Shares Worth $250,000, According to a Recent SEC Filing	Jan. 16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Shattuck Labs, Inc.

Equities

STTK

US82024L1035

Summary

Filters